Literature DB >> 20886613

COLD PCR HRM: a highly sensitive detection method for IDH1 mutations.

Blandine Boisselier1, Yannick Marie, Marianne Labussière, Pietro Ciccarino, Virginie Desestret, XiaoWei Wang, Laurent Capelle, Jean-Yves Delattre, Marc Sanson.   

Abstract

The p.Arg132His mutation of isocitrate dehydrogenase 1 (IDH1(R132H) ) is a frequent alteration and a major prognostic marker in gliomas. However, direct sequencing of highly contaminated tumor samples may fail to detect this mutation. Our objective was to evaluated the sensitivity of a newly described amplification method, coamplification at lower temperature-PCR (COLD PCR), combined with high-resolution melting (HRM) for the detection of the IDH1(R132H) mutation. To this end, we used serial dilutions of mutant DNA with wild-type DNA. PCR-HRM assay detects IDH1(R132H) at an abundance of 25%, similar to the detection limit of direct Sanger sequencing. Introducing a run of COLD PCR allows the detection of 2% mutant DNA. Using two consecutive runs of COLD PCR, we detected 0.25% mutant DNA in a background of wild-type DNA, that mimics a tumor sample highly contaminated by normal DNA. We then analyzed 10 biopsies of tumor edges, considered free of tumor cells by histological analysis, and showed that immunohistochemistry of IDH1(R132H) was positive in three cases (30%), whereas double COLD PCR HRM was positive in the 10 cases studied (100%). In summary, COLD PCR HRM analysis is 100-fold more sensitive than Sanger sequencing, rendering this rapid and powerful strategy particularly useful for samples highly contaminated with normal tissue.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20886613     DOI: 10.1002/humu.21365

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  14 in total

Review 1.  Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.

Authors:  Changcun Guo; Christopher J Pirozzi; Giselle Y Lopez; Hai Yan
Journal:  Curr Opin Neurol       Date:  2011-12       Impact factor: 5.710

Review 2.  COLD-PCR Technologies in the Area of Personalized Medicine: Methodology and Applications.

Authors:  Florence Mauger; Alexandre How-Kit; Jörg Tost
Journal:  Mol Diagn Ther       Date:  2017-06       Impact factor: 4.074

3.  COLD-PCR: improving the sensitivity of molecular diagnostics assays.

Authors:  Coren A Milbury; Jin Li; Pingfang Liu; G Mike Makrigiorgos
Journal:  Expert Rev Mol Diagn       Date:  2011-03       Impact factor: 5.225

Review 4.  IDH mutations in human glioma.

Authors:  Won Kim; Linda M Liau
Journal:  Neurosurg Clin N Am       Date:  2012-05-31       Impact factor: 2.509

5.  Interlaboratory comparison of IDH mutation detection.

Authors:  Martin J van den Bent; C Hartmann; Matthias Preusser; Thomas Ströbel; Hendrikus J Dubbink; Johan M Kros; Andreas von Deimling; Blandine Boisselier; Marc Sanson; Kevin C Halling; Kristin L Diefes; Kenneth Aldape; Caterina Giannini
Journal:  J Neurooncol       Date:  2013-01-29       Impact factor: 4.130

6.  Temperature-tolerant COLD-PCR reduces temperature stringency and enables robust mutation enrichment.

Authors:  E Castellanos-Rizaldos; Pingfang Liu; Coren A Milbury; Minakshi Guha; Angela Brisci; Laura Cremonesi; Maurizio Ferrari; Harvey Mamon; G Mike Makrigiorgos
Journal:  Clin Chem       Date:  2012-05-15       Impact factor: 8.327

7.  Differential strand separation at critical temperature: a minimally disruptive enrichment method for low-abundance unknown DNA mutations.

Authors:  Minakshi Guha; Elena Castellanos-Rizaldos; Pingfang Liu; Harvey Mamon; G Mike Makrigiorgos
Journal:  Nucleic Acids Res       Date:  2012-12-20       Impact factor: 16.971

8.  Novel multiplex bead-based assay for detection of IDH1 and IDH2 mutations in myeloid malignancies.

Authors:  Velizar Shivarov; Milena Ivanova; Evgueniy Hadjiev; Elissaveta Naumova
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.752

9.  An analysis of the prognostic value of IDH1 (isocitrate dehydrogenase 1) mutation in Polish glioma patients.

Authors:  Marzena Anna Lewandowska; Jacek Furtak; Tadeusz Szylberg; Krzysztof Roszkowski; Wiesława Windorbska; Joanna Rytlewska; Wojciech Jóźwicki
Journal:  Mol Diagn Ther       Date:  2014-02       Impact factor: 4.074

10.  IDH mutations: genotype-phenotype correlation and prognostic impact.

Authors:  Xiao-Wei Wang; Pietro Ciccarino; Marta Rossetto; Blandine Boisselier; Yannick Marie; Virginie Desestret; Vincent Gleize; Karima Mokhtari; Marc Sanson; Marianne Labussière
Journal:  Biomed Res Int       Date:  2014-04-30       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.